Back

Pomerantz investigates Dr. Reddy’s after shares fall 9.4%

Verifying
  • Pomerantz LLP is investigating Dr. Reddy’s over alleged securities fraud and unlawful business practices.
  • ₹2.4 billion provision for rejected semaglutide batches contributed to $0.06 quarterly earnings per share.
  • Dr. Reddy’s shares fell 9.4% to $11.38 on July 22, 2026.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.